For adults with systemic lupus erythematosus (SLE) and cutaneous disease, what are the effects of intravenous (IV)/subcutaneous (SC) monoclonal antibodies?

2021 ◽  
Author(s):  
Agustín Ciapponi
Immunotherapy ◽  
2015 ◽  
Vol 7 (3) ◽  
pp. 255-270 ◽  
Author(s):  
Natasha Jordan ◽  
Pamela MK Lutalo ◽  
David P D’Cruz

2020 ◽  
Vol 3 (4) ◽  
pp. e236
Author(s):  
Roberto Lande ◽  
Stefano Alivernini ◽  
Barbara Tolusso ◽  
Francesca Spadaro ◽  
Mario Falchi ◽  
...  

LL37 is a natural antibiotic, but is also a molecule with pleiotropic functions as well as an immune-modulator. LL37 is produced by epithelial cells and is present in neutrophils’ granules. LL37 alone, or in complex with DNA, can activate inflammatory pathways in psoriasis, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In this work, we describe the capacity of two recombinant monoclonal antibodies, RB139 and RB142, previously shown to specifically recognize LL37 in its citrullinated form (cit-LL37) by ELISA, to detect LL37 by immunofluorescence in human inflamed tissues derived from SLE and RA patients. Such antibodies represent previously unavailable tools to detect the presence, the citrullinated state and the exact localization of cit-LL37 in human tissues in health and disease.


2010 ◽  
Vol 3 (1) ◽  
pp. 300-322 ◽  
Author(s):  
Claudio Ponticelli ◽  
Gabriella Moroni

Sign in / Sign up

Export Citation Format

Share Document